Published in J Clin Microbiol on December 01, 2004
Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis (2010) 2.98
Primary culture of Mycobacterium ulcerans from human tissue specimens after storage in semisolid transport medium. J Clin Microbiol (2007) 1.79
Genetic diversity in Mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol (2006) 1.44
Fine-needle aspiration, an efficient sampling technique for bacteriological diagnosis of nonulcerative Buruli ulcer. J Clin Microbiol (2009) 1.34
Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing. PLoS Pathog (2009) 1.33
Optimized method for preparation of DNA from pathogenic and environmental mycobacteria. Appl Environ Microbiol (2008) 1.27
Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens. BMC Infect Dis (2014) 0.97
Mycobacterium africanum is associated with patient ethnicity in Ghana. PLoS Negl Trop Dis (2015) 0.93
Isolation of Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin Microbiol (2011) 0.93
Single nucleotide polymorphisms on the road to strain differentiation in Mycobacterium ulcerans. J Clin Microbiol (2009) 0.86
Isolation of Nontuberculous Mycobacteria from the Environment of Ghanian Communities Where Buruli Ulcer Is Endemic. Appl Environ Microbiol (2016) 0.85
A quick and cost effective method for the diagnosis of Mycobacterium ulcerans infection. BMC Infect Dis (2012) 0.85
Lack of insertional-deletional polymorphism in a collection of Mycobacterium ulcerans isolates from Ghanaian Buruli ulcer patients. J Clin Microbiol (2009) 0.83
Screening of antifungal azole drugs and agrochemicals with an adapted alamarBlue-based assay demonstrates antibacterial activity of croconazole against Mycobacterium ulcerans. Antimicrob Agents Chemother (2012) 0.81
Multicenter external quality assessment program for PCR detection of Mycobacterium ulcerans in clinical and environmental specimens. PLoS One (2014) 0.80
Detection and characterization of drug-resistant conferring genes in Mycobacterium tuberculosis complex strains: A prospective study in two distant regions of Ghana. Tuberculosis (Edinb) (2016) 0.77
Isolation and characterization of nontuberculous mycobacteria from patients with pulmonary tuberculosis in Ghana. Int J Mycobacteriol (2017) 0.76
Clinical and Laboratory Diagnosis of Buruli Ulcer Disease: A Systematic Review. Can J Infect Dis Med Microbiol (2016) 0.76
Mycobacterium ulcerans Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates. PLoS One (2016) 0.75
Evaluating decontamination protocols for the isolation of Mycobacterium ulcerans from swabs. BMC Microbiol (2017) 0.75
Spatio-Temporal Distribution of Mycobacterium tuberculosis Complex Strains in Ghana. PLoS One (2016) 0.75
Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol (1997) 3.96
Direct detection and identification of Mycobacterium ulcerans in clinical specimens by PCR and oligonucleotide-specific capture plate hybridization. J Clin Microbiol (1997) 2.50
Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg (2004) 2.29
Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol (1998) 1.85
Mycobacterium bohemicum cervical lymphadenitis. Pediatr Infect Dis J (2002) 1.15
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med (2005) 4.00
An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J Infect Dis (2005) 3.25
A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem (2003) 2.84
Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis (2002) 2.40
Buruli ulcer disease in Cameroon rediscovered. Am J Trop Med Hyg (2004) 2.29
Multilocus sequence analysis and rpoB sequencing of Mycobacterium abscessus (sensu lato) strains. J Clin Microbiol (2010) 2.19
Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis (2005) 1.95
Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy. Malar J (2009) 1.85
Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis (2011) 1.81
Prevalence of blood-borne infectious diseases in blood donors in Ghana. J Clin Microbiol (2002) 1.77
Synthetic GPI array to study antitoxic malaria response. Nat Chem Biol (2008) 1.67
HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis (2005) 1.58
On the origin of Mycobacterium ulcerans, the causative agent of Buruli ulcer. BMC Genomics (2012) 1.58
Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol (2004) 1.57
Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana. PLoS Med (2007) 1.56
Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis (2011) 1.51
Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS One (2008) 1.51
Multicenter evaluation of the MB/BACT system for susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol (2004) 1.44
Genetic diversity in Mycobacterium ulcerans isolates from Ghana revealed by a newly identified locus containing a variable number of tandem repeats. J Bacteriol (2006) 1.44
Diagnosis of Mycobacterium ulcerans infection (Buruli ulcer) at a treatment centre in Ghana: a retrospective analysis of laboratory results of clinically diagnosed cases. Trop Med Int Health (2008) 1.44
Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect Dis (2008) 1.43
Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS Negl Trop Dis (2013) 1.42
"Pseudo-Beijing": evidence for convergent evolution in the direct repeat region of Mycobacterium tuberculosis. PLoS One (2011) 1.42
Nationwide surveillance of nasopharyngeal Streptococcus pneumoniae isolates from children with respiratory infection, Switzerland, 1998-1999. J Infect Dis (2003) 1.40
Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis (2007) 1.40
Evolution of two distinct phylogenetic lineages of the emerging human pathogen Mycobacterium ulcerans. BMC Evol Biol (2007) 1.39
Single nucleotide polymorphism typing of Mycobacterium ulcerans reveals focal transmission of buruli ulcer in a highly endemic region of Ghana. PLoS Negl Trop Dis (2010) 1.37
European and Developing Countries Clinical Trials Partnership (EDCTP): the path towards a true partnership. BMC Public Health (2009) 1.35
A genome-wide search for type 2 diabetes susceptibility genes in West Africans: the Africa America Diabetes Mellitus (AADM) Study. Diabetes (2004) 1.34
Genomic diversity and evolution of Mycobacterium ulcerans revealed by next-generation sequencing. PLoS Pathog (2009) 1.33
Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey. J Clin Microbiol (2003) 1.33
Genotypic diversity and drug susceptibility patterns among M. tuberculosis complex isolates from South-Western Ghana. PLoS One (2011) 1.31
Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine (2012) 1.30
Optimized method for preparation of DNA from pathogenic and environmental mycobacteria. Appl Environ Microbiol (2008) 1.27
Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol (2006) 1.26
Clonal groupings in serogroup X Neisseria meningitidis. Emerg Infect Dis (2002) 1.20
Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1. Infect Immun (2003) 1.20
Anti-carbohydrate antibodies for the detection of anthrax spores. Angew Chem Int Ed Engl (2006) 1.19
Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther (2009) 1.18
Contiguous spread of Mycobacterium ulcerans in Buruli ulcer lesions analysed by histopathology and real-time PCR quantification of mycobacterial DNA. J Pathol (2006) 1.18
Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. Vaccine (2002) 1.16
Ongoing genome reduction in Mycobacterium ulcerans. Emerg Infect Dis (2007) 1.16
Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J Infect Dis (2007) 1.16
Combining PCR with microscopy to reduce costs of laboratory diagnosis of Buruli ulcer. Am J Trop Med Hyg (2011) 1.15
Mycobacterium bohemicum cervical lymphadenitis. Pediatr Infect Dis J (2002) 1.15
Emergence of W135 meningococcal meningitis in Ghana. Trop Med Int Health (2005) 1.11
Use of diagnostic microarrays for determination of virulence gene patterns of Escherichia coli K1, a major cause of neonatal meningitis. J Clin Microbiol (2005) 1.10
Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol (2011) 1.10
Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop Dis (2013) 1.10
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2012) 1.09
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol (2006) 1.08
The genome, evolution and diversity of Mycobacterium ulcerans. Infect Genet Evol (2012) 1.06
The N'-terminal domain of glyceraldehyde-3-phosphate dehydrogenase of the apicomplexan Plasmodium falciparum mediates GTPase Rab2-dependent recruitment to membranes. Biol Chem (2003) 1.05
Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05
HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis. PLoS Genet (2013) 1.04
A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers. PLoS One (2007) 1.04
Histopathological changes and clinical responses of Buruli ulcer plaque lesions during chemotherapy: a role for surgical removal of necrotic tissue? PLoS Negl Trop Dis (2011) 1.01
Normal CD4+ T lymphocyte levels in HIV seronegative individuals in the Manya/Yilo Krobo communities in the Eastern region of Ghana. Viral Immunol (2006) 1.01
Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis (2009) 1.00
Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans. Appl Environ Microbiol (2009) 1.00
Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med (2005) 1.00
Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children. PLoS One (2011) 0.99
Local activation of the innate immune system in Buruli ulcer lesions. J Invest Dermatol (2006) 0.99
Sero-epidemiology as a tool to screen populations for exposure to Mycobacterium ulcerans. PLoS Negl Trop Dis (2012) 0.98
Whole-blood interferon-gamma release assay for baseline tuberculosis screening of healthcare workers at a Swiss university hospital. Infect Control Hosp Epidemiol (2008) 0.98
Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis (2008) 0.96
Independent loss of immunogenic proteins in Mycobacterium ulcerans suggests immune evasion. Clin Vaccine Immunol (2008) 0.96
Anthrax spore detection by a luminex assay based on monoclonal antibodies that recognize anthrose-containing oligosaccharides. Clin Vaccine Immunol (2010) 0.96
Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem (2012) 0.96
Structure-activity-based design of a synthetic malaria peptide eliciting sporozoite inhibitory antibodies in a virosomal formulation. Chem Biol (2007) 0.94
Research priorities for neglected infectious diseases in Latin America and the Caribbean region. PLoS Negl Trop Dis (2010) 0.94
Neisseria gonorrhoea, Chlamydia trachomatis, and Treponema pallidum infection in antenatal and gynecological patients at Korle-Bu Teaching Hospital, Ghana. Jpn J Infect Dis (2004) 0.93
Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for detection of Leishmania DNA in buffy coat from visceral leishmaniasis patients. Parasit Vectors (2012) 0.93
Isolation of Mycobacterium ulcerans from swab and fine-needle-aspiration specimens. J Clin Microbiol (2011) 0.93
Antibodies elicited by a virosomally formulated Plasmodium falciparum serine repeat antigen-5 derived peptide detect the processed 47 kDa fragment both in sporozoites and merozoites. Peptides (2007) 0.92
Molecular analysis of carbohydrate-antibody interactions: case study using a Bacillus anthracis tetrasaccharide. J Am Chem Soc (2010) 0.91
Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. PLoS One (2012) 0.91
Profile of adverse events in patients receiving treatment for malaria in urban Ghana: a cohort-event monitoring study. Drug Saf (2014) 0.91
Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci U S A (2013) 0.91
Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen. J Immunol (2012) 0.91
Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol (2006) 0.91
Engineered synthetic virus-like particles and their use in vaccine delivery. Chembiochem (2011) 0.90
A genome wide quantitative trait linkage analysis for serum lipids in type 2 diabetes in an African population. Atherosclerosis (2005) 0.90
Synthesis, solution structure and immune recognition of an epidermal growth factor-like domain from Plasmodium falciparum merozoite surface protein-1. Chembiochem (2006) 0.89
A virosomal malaria peptide vaccine elicits a long-lasting sporozoite-inhibitory antibody response in a phase 1a clinical trial. PLoS One (2007) 0.89
Analysis of the Mycobacterium ulcerans genome sequence reveals new loci for variable number tandem repeats (VNTR) typing. Microbiology (2007) 0.89
Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem Biol (2006) 0.88